WO2023174090A1 - Cocristal d'étexilate de dabigatran et son procédé de préparation - Google Patents

Cocristal d'étexilate de dabigatran et son procédé de préparation Download PDF

Info

Publication number
WO2023174090A1
WO2023174090A1 PCT/CN2023/079856 CN2023079856W WO2023174090A1 WO 2023174090 A1 WO2023174090 A1 WO 2023174090A1 CN 2023079856 W CN2023079856 W CN 2023079856W WO 2023174090 A1 WO2023174090 A1 WO 2023174090A1
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
dabigatran etexilate
cocrystal
crystal
solvents
Prior art date
Application number
PCT/CN2023/079856
Other languages
English (en)
Chinese (zh)
Inventor
靳海明
Original Assignee
青岛华麒医药科技创新发展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 青岛华麒医药科技创新发展有限公司 filed Critical 青岛华麒医药科技创新发展有限公司
Publication of WO2023174090A1 publication Critical patent/WO2023174090A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention belongs to the field of medical technology and relates to a co-crystal of dabigatran etexilate and a preparation method, a pharmaceutical composition containing the co-crystal, and the application of the co-crystal in the preparation of anticoagulant drugs.
  • Dabigatran etexilate (chemical name: 3-[[[2-[[[4-[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1 -Methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionate ethyl ester, formula 1) is a new thrombin inhibitor used to prevent stroke and thrombosis. Dabigatran etexilate is the prodrug of dabigatran. Its mechanism of action is that after oral administration, it is rapidly converted into biologically active dabigatran by non-specific esterases in the intestine, liver and blood.
  • dabigatran etexilate competitively binds to the activation site of thrombin to inhibit thrombin, which significantly reduces the risk of bleeding while ensuring anticoagulant efficacy.
  • dabigatran etexilate is more effective and safer, does not require special medication monitoring, and has good application prospects.
  • the water solubility of dabigatran etexilate is extremely poor, less than 3 ⁇ g/ml, and has significant pH dependence. It is easy to crystallize and precipitate in the gastrointestinal tract. Due to its insoluble and weakly alkaline characteristics, it causes bioavailability problems. greatly limits its clinical application.
  • compositions are pharmaceutical active ingredients (API) and cocrystal ligands (cocrystals former, CCF) in a fixed stoichiometric ratio through hydrogen bonds, van der Waals forces, ⁇ - ⁇ conjugation and halogen bonds and other non-conjugated substances.
  • a multi-component system composed of covalent bonds.
  • Drug co-crystals can improve the physical and chemical properties of drugs, such as melting point, stability, solubility and bioavailability, without changing the chemical structure of the drug.
  • drug cocrystals have become a new strategy for drug research and development, showing attractive application prospects in the field of medical biology.
  • the inventor unexpectedly obtained a co-crystal of dabigatran etexilate, which improved the solubility, dissolution and in vivo relative bioavailability of poorly soluble dabigatran etexilate compared with the prior art.
  • the present invention provides a co-crystal comprising dabigatran etexilate and a co-crystal ligand, where the co-crystal ligand is a pharmaceutically acceptable organic acid.
  • the present invention also provides a pharmaceutical composition, which contains the co-crystal and a pharmaceutically acceptable carrier or excipient.
  • the invention also provides a method for preparing the eutectic, including:
  • the crystals are isolated and optionally dried.
  • the present invention also provides another method for preparing the eutectic, including:
  • the present invention also provides the use of the cocrystal in preparing drugs for anticoagulation.
  • the present invention also provides the use of the cocrystal in the preparation of drugs for treating and/or preventing thrombosis.
  • the present application provides a co-crystal comprising dabigatran etexilate and a co-crystal ligand, the co-crystal ligand being an organic acid selected from p-hydroxybenzoic acid and 2,4-dihydroxybenzoic acid. , succinic acid, benzoic acid, tartaric acid, maleic acid, fumaric acid or any combination thereof.
  • the organic acid is p-hydroxybenzoic acid or 2,4-dihydroxybenzoic acid.
  • the organic acid is 2,4-dihydroxybenzoic acid.
  • the molar ratio of dabigatran etexilate to the co-crystal ligand is about 1:0.5-50, preferably about 1:0.5-25, more preferably about 1:0.5 ⁇ 10, more preferably about 1:0.5 ⁇ 5.
  • the co-crystal ligand is p-hydroxybenzoic acid, 2,4-dihydroxybenzoic acid, or succinic acid.
  • the molar ratio of dabigatran etexilate to the co-crystal ligand is about 1:0.5 ⁇ 5, about 1:0.8 ⁇ 4, about 1:0.8 ⁇ 3, about 1:0.8 ⁇ 2.5 , about 1:0.8 ⁇ 1.5, about 1:0.8 ⁇ 1.2, for example, about 1:1.
  • the co-crystal is a co-crystal of dabigatran etexilate and p-hydroxybenzoic acid or 2,4-dihydroxybenzoic acid, and the molar ratio of dabigatran etexilate to the co-crystal ligand is about 1:1.
  • the co-crystal ligand in the co-crystal, is 2,4-dihydroxybenzoic acid, and the The molar ratio of dabigatran etexilate to cocrystal ligand is approximately 1:1.
  • the co-crystal of dabigatran etexilate and 2,4-dihydroxybenzoic acid has an X-ray powder diffraction pattern expressed at an angle of 2 ⁇ obtained using Cu-K ⁇ radiation at 20.7 There are characteristic peaks at ° ⁇ 0.2° and 24.9° ⁇ 0.2°.
  • the co-crystal of dabigatran etexilate and 2,4-dihydroxybenzoic acid, in an X-ray powder diffraction pattern expressed at a 2 ⁇ angle obtained using Cu-K ⁇ radiation also has There are characteristic peaks at 17.9° ⁇ 0.2°, 22.1° ⁇ 0.2°, 23.2° ⁇ 0.2°, and 24.1° ⁇ 0.2°.
  • the co-crystal of dabigatran etexilate and 2,4-dihydroxybenzoic acid, in an X-ray powder diffraction pattern expressed at a 2 ⁇ angle obtained using Cu-K ⁇ radiation also has There are characteristic peaks at 21.9° ⁇ 0.2°, 26.4° ⁇ 0.2°, 27.1° ⁇ 0.2°, and 28.5° ⁇ 0.2°.
  • the co-crystal of dabigatran etexilate and 2,4-dihydroxybenzoic acid, in an X-ray powder diffraction pattern expressed at a 2 ⁇ angle obtained using Cu-K ⁇ radiation also has There are characteristic peaks at 9.5° ⁇ 0.2°, 11.0° ⁇ 0.2°, 22.6° ⁇ 0.2°, and 27.1° ⁇ 0.2°.
  • the co-crystal of dabigatran etexilate and 2,4-dihydroxybenzoic acid, in an X-ray powder diffraction pattern expressed at a 2 ⁇ angle obtained using Cu-K ⁇ radiation also has 17.8° ⁇ 0.2°, 18.7° ⁇ 0.2°, 25.7° ⁇ 0.2°, 9.9° ⁇ 0.2°, 19.1° ⁇ 0.2°, 18.9° ⁇ 0.2°, 20.3° ⁇ 0.2°, 21.5° ⁇ 0.2°, 17.0° There are characteristic peaks at ⁇ 0.2° and 28.3° ⁇ 0.2°.
  • the cocrystal of dabigatran etexilate and 2,4-dihydroxybenzoic acid has substantially the same X-ray powder diffraction pattern as shown in Figure 5 using Cu-K ⁇ radiation.
  • the dabigatran etexilate has a higher concentration of 2,4 -The cocrystal of dihydroxybenzoic acid has no characteristic peaks at 8.9° ⁇ 0.2° and 15.5° ⁇ 0.2°, and has characteristic peaks at 20.7° ⁇ 0.2° and 24.9° ⁇ 0.2°.
  • the dabigatran etexilate drug substance has an X-ray powder diffraction pattern substantially the same as shown in Figure 6 using Cu-K ⁇ radiation.
  • the co-crystal of dabigatran etexilate and 2,4-dihydroxybenzoic acid exhibits melting in the range of 120°C to 130°C as measured by differential scanning calorimetry (DSC) Endothermic phenomenon.
  • the co-crystal of dabigatran etexilate and 2,4-dihydroxybenzoic acid has substantially the same differential scanning volume as shown in Figure 8 as measured by differential scanning calorimetry. Thermal curve.
  • the present application also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the co-crystal described in any one of the above, and a pharmaceutically acceptable carrier or excipient.
  • the co-crystal is present in the pharmaceutical composition in an anticoagulant effective amount.
  • the application also provides a method for preparing the cocrystal of the present invention, comprising:
  • the solvent is selected from water, alcohol solvents, ester solvents, ketone solvents, ether solvents, nitrile solvents, alkane solvents, halogenated alkane solvents, or any combination thereof.
  • the alcoholic solvent is selected from methanol, ethanol, isopropyl alcohol, or any combination thereof.
  • the ester solvent is selected from methyl acetate, ethyl acetate, propyl acetate, or any combination thereof.
  • the ketone solvent is selected from acetone, methyl isobutyl ketone, or combinations thereof.
  • the ether solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran, or any combination thereof.
  • the nitrile solvent is acetonitrile.
  • the alkane solvent is n-hexane.
  • the haloalkane solvent is methylene chloride.
  • the solvent is selected from methanol, ethanol, tert-butyl methyl ether, n-hexane, water, or any combination thereof.
  • the application also provides another method for preparing the cocrystal of the present invention, including:
  • the solvent is selected from alcohol solvents, ester solvents, ketone solvents, ether solvents, nitrile solvents, alkane solvents, halogenated alkane solvents, or any combination thereof.
  • the alcoholic solvent is selected from methanol, ethanol, isopropyl alcohol, or any combination thereof.
  • the ester solvent is selected from methyl acetate, ethyl acetate, propyl acetate, or any combination thereof.
  • the ketone solvent is selected from acetone, methyl isobutyl ketone, or combinations thereof.
  • the ether solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran, or any combination thereof.
  • the nitrile solvent is acetonitrile.
  • the alkane solvent is n-hexane.
  • the haloalkane solvent is methylene chloride.
  • the solvent is n-hexane.
  • This application also provides the use of the cocrystal of the present invention in the preparation of anticoagulant drugs.
  • This application also provides the use of the cocrystal of the present invention in the preparation of medicaments for the treatment and/or prevention of thrombosis.
  • the application also provides the use of the cocrystal of the invention in the preparation of medicaments for the treatment and/or prevention of venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and systemic embolism.
  • VTE venous thromboembolism
  • DVD deep vein thrombosis
  • PE pulmonary embolism
  • stroke stroke and systemic embolism.
  • the term "substantially the same" used to qualify a figure is intended to mean that a person skilled in the art would consider the figure to be identical to the reference figure, taking into account acceptable deviations in the art. Such deviations may be caused by factors known in the art related to instrumentation, operating conditions, and human factors. For example, those skilled in the art will appreciate that endothermic onset and peak temperatures measured by differential scanning calorimetry (DSC) can vary significantly from experiment to experiment.
  • DSC differential scanning calorimetry
  • two graphs are considered to be substantially the same when the positions of characteristic peaks of the two graphs do not vary by more than ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, or ⁇ 1%.
  • two X-ray diffraction patterns are considered to be substantially the same when the 2 ⁇ angle of the characteristic peaks of the two X-ray diffraction patterns does not change by more than ⁇ 0.3°, ⁇ 0.2°, or ⁇ 0.1°.
  • the term "effective amount” refers to an amount sufficient to achieve the desired therapeutic or preventive effect, for example, an amount that reduces symptoms associated with the disease to be treated (e.g., thrombosis), or is effective to avoid, reduce, An amount that prevents or delays the onset of a disease, such as a blood clot. Determining such effective amounts is within the ability of those skilled in the art. Generally speaking, the daily dosage of the cocrystal of the present invention for treatment can be about 1 to 1000 mg.
  • treatment is intended to alleviate, lessen, ameliorate, or eliminate the disease state or disorder targeted. If a subject receives a therapeutic amount of the co-crystal or pharmaceutical composition in accordance with the methods described herein, the subject exhibits an observable and/or detectable reduction in one or more signs and symptoms. or improved, the subject was successfully "treated”. It should also be understood that treatment of a disease state or disorder includes not only complete treatment; It does not achieve a complete cure, but achieves some biologically or medically relevant results.
  • prevention is intended to avoid, reduce, prevent or delay the occurrence of a disease or disease-related symptoms before such disease or disease-related symptoms occur prior to the administration of the relevant drug. "Prevention” does not necessarily require completely preventing the occurrence of a disease or disease-related symptoms. For example, administration of a drug can reduce the risk of a subject developing a specific disease or disease-related symptoms, or attenuate the severity of subsequent related symptoms. All can be considered as "preventing" the emergence or development of the disease.
  • the term "about” shall be understood to mean within the normal tolerance range in the art, for example, about may be understood to mean ⁇ 10%, ⁇ 9%, ⁇ 8%, ⁇ 7%, ⁇ Within 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1%, ⁇ 0.5%, ⁇ 0.1%, ⁇ 0.05% or ⁇ 0.01%. All numerical values provided herein are modified by the term “about” unless otherwise apparent from context.
  • the term "pharmaceutically acceptable carrier or excipient” refers to a diluent, addendum, or vehicle that is administered with a therapeutic agent and that is, within the scope of sound medical judgment, suitable Exposure to human and/or other animal tissue without undue toxicity, irritation, allergic reactions, or other problems or complications commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable carriers that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, sterile liquids, such as water, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water is an exemplary carrier when the pharmaceutical composition is administered intravenously. Physiological saline and aqueous glucose and glycerol solutions may also be used as liquid carriers, particularly for injections.
  • Suitable excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerin, propylene glycol, water, ethanol wait.
  • the composition may also contain a small amount of a wetting agent, an emulsifier, a pH buffer, a preservative, an antioxidant, a flavoring agent, a fragrance, a co-solvent, a solubilizer, an osmotic pressure regulator, a coloring agent, etc., if necessary.
  • Oral formulations may contain standard carriers such as binders, fillers, disintegrating agents, lubricants, and the like.
  • the pharmaceutical composition of the present invention can be administered by methods known in the art, such as but not limited to administration in any of the following ways: oral administration, spray inhalation, rectal administration, nasal administration, buccal administration, topical administration, parenteral administration
  • the drug is administered by subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal and intracranial injection or infusion, or by means of an explanted reservoir.
  • oral, intramuscular or intravenous injection administration is preferred.
  • compositions of the present invention can be administered in suitable dosage forms.
  • the dosage form may be a solid preparation, a semi-solid preparation, a liquid preparation or a gaseous preparation, including but not limited to tablets, Capsules, powders, granules, lozenges, hard candies, powders, sprays, creams, ointments, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions , suspensions, elixirs, syrups.
  • the pharmaceutical composition of the present invention can be prepared by any method well known in the art, such as by mixing, dissolving, granulating, sugar coating, grinding, emulsifying, lyophilizing and other processes.
  • the co-crystal of dabigatran etexilate Compared with the dabigatran etexilate API, the co-crystal of dabigatran etexilate provided by the present invention has one or more of the following advantages:
  • the present invention utilizes the principles of crystal engineering, combined with the characteristics of the presence of amide groups in the structure of dabigatran etexilate, and uses a cooling crystallization method or a solvent method to increase the opportunity for intermolecular contact and accelerate the eutectic formation rate.
  • Figure 1 shows the equilibrium solubility results of dabigatran etexilate and the product obtained in Example 1 of the present invention
  • Figure 2 shows the equilibrium solubility results of dabigatran etexilate and the product obtained in Example 2 of the present invention
  • Figure 3 shows the in vitro dissolution curves of dabigatran etexilate and the product obtained in Example 1 of the present invention
  • Figure 4 shows the in vitro dissolution curves of dabigatran etexilate and the product obtained in Example 2 of the present invention
  • Figure 5 shows the XRPD pattern of the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 1 of the present invention
  • Figure 6 shows the XRPD pattern of dabigatran etexilate API
  • Figure 7 shows the dabigatran etexilate/2,4-dihydroxybenzoic acid co-crystal prepared in Example 1 of the present invention and dabigatran etexilate, 2,4-dihydroxybenzoic acid, dabigatran etexilate/ XRPD comparison pattern of physical mixture of 2,4-dihydroxybenzoic acid;
  • Figure 8 shows the DSC chart of the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 1 of the present invention. Spectrum;
  • Figure 9 shows the DSC comparison spectra of dabigatran etexilate, 2,4-dihydroxybenzoic acid, and the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 1 of the present invention
  • Figure 10 shows the FTIR spectrum of dabigatran etexilate
  • Figure 11 shows the FTIR spectrum of 2,4-dihydroxybenzoic acid
  • Figure 12 shows the FTIR spectrum of the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 1 of the present invention.
  • Dabigatran etexilate used in the embodiments of the present invention is either commercially available (Hanxiang Biotechnology Co., Ltd., product number BCP02864, batch number 20200705), or can be prepared by referring to existing technologies. All co-crystal ligands used are commercially available.
  • All co-crystal ligands used are commercially available.
  • p-hydroxybenzoic acid, 2,4-dihydroxybenzoic acid, succinic acid, nicotinamide, benzamide, and urea can be purchased from Sinopharm Chemical Reagent Co., Ltd.; isoniazid Bases can be purchased from Aladdin Reagents Ltd.
  • Example 1 Preparation of dabigatran etexilate cocrystal by cooling crystallization method
  • Dabigatran etexilate and 7 co-crystal ligands were used in molar ratios. After mixing 1:1, dissolve in 10 ml methanol solvent, stir at 350 rpm for 6 hours, then cool down at 10°C/h until crystals precipitate, maintain for 3 hours, then filter with suction to obtain a sample, and dry the sample under reduced pressure to obtain the product.
  • Dabigatran etexilate and 7 co-crystal ligands were used in molar ratios. After mixing 1:1, dissolve in ethanol solvent, stir at 200 rpm for 3 hours, slowly add water dropwise to the solution, mix while adding, and then place at room temperature to slowly evaporate. When a large number of crystals are produced, suck out the remaining liquid and reduce the pressure. Drying gives the product.
  • Test method Using water as the solvent, add an excess of dabigatran etexilate API and each product obtained in Example 1 and Example 2, and add a small amount of small glass beads. After sealing, shake at a constant temperature of 37°C and centrifuge. Clear, 0.45 ⁇ m Filtrate through a microporous membrane, and the filtrate obtained is the test solution; in addition, accurately weigh about 5 mg of the dabigatran etexilate API as the reference substance, and dilute it to an appropriate concentration to form the reference substance solution. According to the high performance liquid chromatography method, the peak areas of the test solution and the reference solution were measured at 225 nm, and the content and equilibrium solubility were calculated by the external standard method.
  • Test method Use 900 ml of aqueous solution as the dissolution medium, add an appropriate amount of dabigatran etexilate and each product obtained in the above Example 1 and Example 2, and follow the dissolution determination method (2020 version of Chinese Pharmacopoeia General Chapter 0931 Second Method), 37°C, rotating speed is 75rpm, operate according to the law, take 5ml of the solution at 5, 10, 15, 20, 30, 45, 60, 90, 120, 180 and 240 minutes respectively, and filter it with a 0.45 ⁇ m microporous membrane to obtain the test solution ; In addition, accurately weigh the dabigatran etexilate raw material medicinal dissolution medium and dilute it to an appropriate concentration to prepare a reference solution. According to the chromatographic conditions in Test Example 1, use high-performance liquid chromatography to measure the peak areas of the test solution and the reference solution at 225 nm, calculate the dissolution amounts at different time points using the external standard method, and draw a cumulative dissolution curve.
  • the in vitro dissolution curve of each product obtained in Example 1 is shown in Figure 2.
  • the results show that the product with 2,4-dihydroxybenzoic acid, p-hydroxybenzoic acid, and succinic acid as ligands can be completely dissolved within 90 minutes (> 80%), indicating that the above three ligands and dabigatran etexilate all form a co-crystal, achieving the effect of improving in vitro dissolution; while the in vitro dissolution of dabigatran etexilate API and the products of the remaining four ligands The degrees are all less than ⁇ 20%, indicating that no eutectic is formed.
  • Test Example 3 Characterization of dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal
  • XRPD X-ray Characterized by powder diffraction
  • DSC differential scanning calorimetry
  • FTIR Fourier transform infrared spectroscopy
  • Example 1 Use a Bruker D8 Advance diffractometer (Bruker, Germany) to measure the powder diffraction pattern of the drug cocrystal obtained in Example 1.
  • the test conditions are as follows: Cu, K ⁇ , 40kV, 40mV as light source, step length 0.0128°, scanning range 3 ⁇ 45°C, room temperature.
  • the powder diffraction patterns of dabigatran etexilate, 2,4-dihydroxybenzoic acid, and dabigatran etexilate/2,4-dihydroxybenzoic acid physical mixture (molar ratio 1:1) were obtained .
  • the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 1 has characteristic peaks at 2 ⁇ (°) of 20.7° ⁇ 0.2° and 24.9° ⁇ 0.2°; There are also characteristic peaks at 17.9° ⁇ 0.2°, 22.1° ⁇ 0.2°, 23.2° ⁇ 0.2°, and 24.1° ⁇ 0.2°; there are also characteristic peaks at 21.9° ⁇ 0.2°, 26.4° ⁇ 0.2°, 27.1° ⁇ 0.2°, There are characteristic peaks at 28.5° ⁇ 0.2°; there are also characteristic peaks at 9.5° ⁇ 0.2°, 11.0° ⁇ 0.2°, 22.6° ⁇ 0.2°, and 27.1° ⁇ 0.2°; and at 17.8° ⁇ 0.2° and 18.7°.
  • the XRPD pattern of the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 1 is shown in Figure 5.
  • the XRPD pattern of dabigatran etexilate API is shown in Figure 6.
  • Figure 7 shows the dabigatran etexilate/2,4-dihydroxybenzoic acid co-crystal prepared in Example 1 and dabigatran etexilate, 2,4-dihydroxybenzoic acid, and dabigatran etexilate/2, Comparative XRPD patterns of physical mixtures of 4-dihydroxybenzoic acid. Both dabigatran etexilate and 2,4-dihydroxybenzoic acid show obvious characteristic peaks, indicating that both have crystal structures; the characteristic peak of the dabigatran etexilate/2,4-dihydroxybenzoic acid physical mixture is dabigatran etexilate/2,4-dihydroxybenzoic acid.
  • a simple superposition of the characteristic peaks of gatran etexilate and 2,4-dihydroxybenzoic acid shows that there is no interaction between the API and the ligand 2,4-dihydroxybenzoic acid in the physical mixture; compared with dabigatran etexilate API , the X-ray powder diffraction of the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal of the present invention has characteristics at diffraction angles 2 ⁇ (error ⁇ 0.2 degrees) of 8.9° ⁇ 0.2° and 15.5° ⁇ 0.2°. The peak disappears, and there are characteristic peaks at 20.7° ⁇ 0.2° and 24.9° ⁇ 0.2°, indicating that a new structure is formed in the eutectic.
  • the XRPD pattern of the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 2 is basically the same as Figure 5.
  • Example 2 Use TA Q2000 differential scanning calorimeter (TA Instruments) to measure the drug eutectic obtained in Example 1.
  • the test conditions are as follows: about 5 mg of the sample is packaged in an aluminum disk, the heating temperature is 25-300°C, and the heating rate is 10.0°C/ min, purge gas 50ml/min nitrogen, temperature calibration using NIST indium metal. Under the same test conditions, the DSC spectra of dabigatran etexilate and 2,4-dihydroxybenzoic acid were obtained.
  • Figure 8 shows the DSC spectrum of the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 1.
  • picture 9 shows the DSC comparison spectra of dabigatran etexilate, 2,4-dihydroxybenzoic acid, and the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 1.
  • the melting points of dabigatran etexilate, 2,4-dihydroxybenzoic acid, and dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal are 134.4°C, 219.4°C, and 122.8°C.
  • a change in melting point indicates the formation of a new phase.
  • Example 1 Use a Nicolet 6700 Fourier transform infrared spectrometer (Thermo Fisher Scientific) to measure the drug cocrystal obtained in Example 1.
  • the test conditions are as follows: use KBr dry tableting, and the scanning range is 4000 to 400 cm -1 .
  • Figure 10, Figure 11, and Figure 12 respectively show the FTIR of dabigatran etexilate, 2,4-dihydroxybenzoic acid, and the dabigatran etexilate/2,4-dihydroxybenzoic acid cocrystal prepared in Example 1. Map.
  • Test Example 4 In vivo pharmacokinetic test on beagle dogs
  • Test method Take 9 male beagle dogs (purchased from Beijing Mars Biotechnology Co., Ltd.), weighing 9.5kg ⁇ 1.0kg, and randomly divide them into three groups: test preparation group 1 (dabigatran etexilate/2,4 -Dihydroxybenzoic acid co-crystal group), test preparation group 2 (dabigatran etexilate/2,4-dihydroxybenzoic acid physical mixture group) and reference preparation group (dabigatran etexilate API group), 3 per group. Fast for 12 hours the day before the experiment and drink water freely. The two groups of beagle dogs were administered dabigatran etexilate at a dose equivalent to 150 mg.
  • blood was collected from the leg vein at 10min, 30min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, and 48h respectively.
  • After collecting the blood place it in a heparinized blood collection tube and centrifuge for 10 minutes. Precisely measure 100 ⁇ l of plasma and add it to the EP tube. Add 10 ⁇ l of verapamil internal standard solution (50ng/ml), mix well, add 0.4 ml of methanol, and vortex for 3 minutes. Centrifuge at 14000 r/min for 5 minutes; inject 5 ⁇ L of the supernatant, measure and calculate the blood drug concentration by LC-MS/MS, and calculate the pharmacokinetic parameters with DASS2.0 software.
  • Chromatographic column Agilent narrow Bore RR SB-C18 column (specification: 2.1mm ⁇ 100mm, 3.5 ⁇ m); mobile phase: 0.1% formic acid aqueous solution (B): methanol (A), gradient elution: 0min90%B ⁇ 0.5min10% B ⁇ 2min10%B ⁇ 2.01min 90%B; flow rate: 0.3ml/min; injection volume: 5 ⁇ l; column temperature: 40°C.
  • Ion polarity positive ions
  • ionization method pneumatic-assisted electrospray ionization (ESI)
  • ion detection method multiple reaction monitoring (MRM); detection object: DE[M+H]+, m/z 628.1 ⁇ 289.0, Internal standard [M+H]+, m/z455.2 ⁇ 165.1; fragmentation voltages: 110V and 160V respectively; collision energy: DE 40eV, internal standard 30eV, drying gas flow rate: 10L/min; spray chamber pressure: 50psi; drying gas temperature: 350°C, capillary voltage: 4000V.
  • the obtained blood drug concentration data were analyzed by DAS 2.0 analysis software.
  • Beagle dogs were orally administered dabigatran etexilate API, dabigatran etexilate/2,4-dihydroxybenzoic acid co-crystal prepared in Example 1, and dabigatran etexilate/2,4-dihydroxybenzoic acid. After physical mixture, the main pharmacokinetic parameters and relative bioavailability were calculated based on the average blood drug concentration ( ⁇ g/mL) at different time points. The results are shown in Table 1 and Table 2.
  • AUC 0 ⁇ Tn and AUC 0 ⁇ are the areas under the plasma concentration curve at 0 ⁇ Tn and 0 ⁇ times respectively, and C max and T max are the peak concentration and peak time respectively.
  • Relative bioavailability AUC test preparation /AUC reference preparation .
  • the dabigatran etexilate cocrystal provided by the present invention has a simple prescription and imparts new physical and chemical properties to the active ingredient dabigatran etexilate without changing the molecular structure of the drug.
  • the in vitro dissolution curve and the in vivo pharmacokinetics experimental results of beagle dogs show that the drug cocrystal provided by the present invention is superior to the dabigatran etexilate API and the physical mixture of the same proportion, and has the advantages of simple preparation process, low cost, and ease of use. It has the advantages of operation, stable quality, strong controllability, good reproducibility, and high bioavailability, and has potential application value.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

La présente invention concerne un co-cristal d'étéxilate de dabigatran et son procédé de préparation, ainsi qu'une composition pharmaceutique comprenant le co-cristal, et concerne en outre l'utilisation du co-cristal dans la préparation d'un médicament anticoagulant. Le co-cristal comprend de l'étéxilate de dabigatran et un agent de formation de co-cristal, l'agent de formation de co-cristal étant un type spécifique d'acide organique. Le co-cristal présente les avantages d'une solubilité élevée, d'un taux de dissolution in vitro élevé, d'une biodisponibilité relative in vivo élevée, et analogues.
PCT/CN2023/079856 2022-03-15 2023-03-06 Cocristal d'étexilate de dabigatran et son procédé de préparation WO2023174090A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210252943.8A CN116789640A (zh) 2022-03-15 2022-03-15 达比加群酯共晶及其制备方法
CN202210252943.8 2022-03-15

Publications (1)

Publication Number Publication Date
WO2023174090A1 true WO2023174090A1 (fr) 2023-09-21

Family

ID=88022366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/079856 WO2023174090A1 (fr) 2022-03-15 2023-03-06 Cocristal d'étexilate de dabigatran et son procédé de préparation

Country Status (2)

Country Link
CN (1) CN116789640A (fr)
WO (1) WO2023174090A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2610251A1 (fr) * 2011-12-29 2013-07-03 Zaklady Farmaceutyczne Polpharma SA Nouvelles formes polymorphes de dabigatran etexilate et leur procédé de préparation
WO2013124749A1 (fr) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Nouveau polymorphe d'étéxilate de dabigatran
WO2014020546A2 (fr) * 2012-07-31 2014-02-06 Ranbaxy Laboratories Limited Formes cristallines d'étexilate de dabigatran et leur procédé de préparation
US20170165247A1 (en) * 2014-07-18 2017-06-15 Olon S.P.A. Crystalline compounds of dabigatran etexilate
WO2019008605A1 (fr) * 2017-07-07 2019-01-10 Zim Laboratories Limited Nouveau co-cristal pharmaceutique d'étéxilate de dabigatran

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2610251A1 (fr) * 2011-12-29 2013-07-03 Zaklady Farmaceutyczne Polpharma SA Nouvelles formes polymorphes de dabigatran etexilate et leur procédé de préparation
WO2013124749A1 (fr) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Nouveau polymorphe d'étéxilate de dabigatran
WO2014020546A2 (fr) * 2012-07-31 2014-02-06 Ranbaxy Laboratories Limited Formes cristallines d'étexilate de dabigatran et leur procédé de préparation
US20170165247A1 (en) * 2014-07-18 2017-06-15 Olon S.P.A. Crystalline compounds of dabigatran etexilate
WO2019008605A1 (fr) * 2017-07-07 2019-01-10 Zim Laboratories Limited Nouveau co-cristal pharmaceutique d'étéxilate de dabigatran

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutics", 30 April 2020, CHINA MEDICAL SCIENCE AND TECHNOLOGY PRESS, CN, ISBN: 978-7-5214-1761-6, article QI, XIAOLE: "XI. Pharmaceutical Co- crystal Technology", pages: 379 - 381, XP009549916 *
GAWADE A R, BOLDHANE S P: "SOLID DOSAGE FORM DEVELOPMENT OF DABIGATRAN ETEXILATE MESYLATE WITH INCREASED SOLUBILITY AND DISSOLUTION USING COCRYSTALLIZATION", INTERNALTIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, SOCIETY OF PHARMACEUTICAL SCIENCES AND RESEARCH, PNACHKULA (HR), IN, vol. 11, no. 6, 1 June 2020 (2020-06-01), IN , XP093092654, ISSN: 2320-5148, DOI: 10.13040/IJPSR.0975-8232.11(5).2899-05 *
ZHANG, XIAOMING: "Pharmaceutical Co-crystal Synthesis, Representation and Property Research", CHINA DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, ENGINEERING SCIENCE AND TECHNOLOGY 1, 1 June 2016 (2016-06-01), CN, pages 1 - 129, XP009548967 *

Also Published As

Publication number Publication date
CN116789640A (zh) 2023-09-22

Similar Documents

Publication Publication Date Title
CN100558351C (zh) 化合物和释放前列环素类似物的方法
KR20210129128A (ko) Fxr 효능제의 고체 형태
CN110759908B (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
TW200908970A (en) Azapeptide derivatives
EP3490978B1 (fr) Sels de dérivés de 2, 6-diméthylpyrimidone et leurs utilisations
JP4537197B2 (ja) 即時放出性医薬製剤
KR20220008264A (ko) 염증성 장애를 치료하기 위한 화합물 및 방법
TWI540131B (zh) 阿瑞吡坦（ａｐｒｅｐｉｔａｎｔ）ｌ－脯胺酸組成物及共晶體
JP2018522918A (ja) ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソル−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の新規結晶形態及びその製造方法
RU2761825C1 (ru) Соединения дейтерированного дефактиниба и их применение
WO2023174090A1 (fr) Cocristal d'étexilate de dabigatran et son procédé de préparation
JP2020505355A (ja) Ｇｆｔ−５０５の結晶形及びその製造方法並びに用途
US20200181064A1 (en) Pharmaceutically acceptable salts of fatty acids
JP2019509306A (ja) Ｊａｋ関連疾患の治療又は予防に用いる薬物の塩酸塩の結晶形及びその製造方法
WO2019134455A1 (fr) Nouvelle forme cristalline d'acalabrutinib, son procédé de préparation et son utilisation
WO2019228330A1 (fr) Composé de benzo[d]imidazole substitué et composition pharmaceutique associée
TW200301114A (en) Crystals of taxane derivative and process for the production thereof
CN117126148A (zh) 利伐沙班共晶及其制备方法
CN115141136B (zh) 特考韦瑞药的共晶及其制备方法
EP4286385A1 (fr) Nouveau maléate d'un dérivé de triazolopyrazine, composition, procédé d'utilisation et procédé de préparation associé
CN117903050B (zh) 阿立哌唑共晶及其药物组合物和应用
US20230346956A1 (en) Complex of 7-deacetylforskolin and pvp
WO2023143427A1 (fr) Forme cristalline de arv-110, son procédé de préparation et son utilisation
EP3822264A1 (fr) Formes cristallines d'un dérivé d'oxypyridine amide et leur procédé de préparation
TW202333739A (zh) 二肽基肽酶1抑制劑多晶型物及其製備方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23769596

Country of ref document: EP

Kind code of ref document: A1